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Background: Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents. Over the last years,
decreased gonococcal susceptibility to third-generation cephalosporins, especially cefixime, emerged worldwide.
Therefore, current international guidelines recommend dual therapy for gonorrhoea with ceftriaxone plus either
azithromycin or doxycycline. Gonococcal susceptibility data in Switzerland are sparse.
Methods: We investigated the prevalence of antibiotic susceptibility of N. gonorrhoeae in specimens collected
between 1990 and 2012 at the University of Zurich, Switzerland. Minimum inhibitory concentrations (MICs) for
cefixime, ceftriaxone, ciprofloxacin, and penicillin were determined by Etests. The European Committee on
Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used to define reduced susceptibility.
Results: A total of 320 isolates were tested. Between 1990 and 2006 all tested samples were susceptible to both
cephalosporins. Subsequently, the prevalence of elevated MICs for cefixime increased to 10.4% (2007/2008), 11.5%
(2009/2010), and 11.4% (2011/2012); and for ceftriaxone to 2.4% (2007/2008), 4.7% (2009/2010), and 0% (2011/2012),
respectively. The prevalence of resistance to ciprofloxacin (72.7%) and penicillin (22.7%) was high in 2011/2012.
Conclusions: Decreasing susceptibility of N. gonorrhoeae to third-generation cephalosporins in Switzerland supports
treatment recommendations with ceftriaxone plus azithromycin or doxycycline. Health-care providers need to be
aware of possible treatment failures with cephalosporins. Continued surveillance of gonococcal antimicrobial resistance
is essential.
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Infections with Neisseria gonorrhoeae may cause serious
complications, including pelvic inflammatory disease, infer-
tility, peritonitis, and chronic pain, and it enhances HIV
transmission [1,2]. Effective treatment of gonorrhoea is
mandatory to control disease transmission and prevent
sequelae. However, N. gonorrhoeae rapidly developed
antimicrobial resistance to all previously recommended
first-line drugs, including penicillins, tetracyclines, and* Correspondence: helen.kovari@usz.ch
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stated.fluoroquinolones. Third-generation cephalosporins, such
as cefixime and ceftriaxone, remain the only readily avai-
lable active antimicrobial class. In recent years, however,
gonococcal strains with reduced susceptibility to cefixime
emerged and spread worldwide [3]. Clinical treatment fail-
ures with cefixime have been reported in Japan, several
European countries, Canada, and South Africa [4-10]. In
2009, the first treatment failures to ceftriaxone were ob-
served in Australia [11] and 2010 in Sweden [12]. Cur-
rently, the identification of extensively drug-resistant
(XDR) N. gonorrhoeae strains with high-level ceftriaxone
resistance in Japan [13], France [14], and Spain [15], are of
major concern. In addition to high ceftriaxone minimumtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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typically multidrug-resistant, exhibiting additional re-
sistance to fluoroquinolones as well as to older drugs.
Consequently, most treatment guidelines now recom-
mend combination therapy with the injectable agent
ceftriaxone plus either azithromycin or doxycycline in-
stead of oral monotherapy with cefixime [16,17].
In Switzerland, a strong rise in N. gonorrhoeae infec-
tions was observed during the past decade. Notifications
have increased nearly threefold, with 521 reported cases
in 2003, and 1569 cases in 2012, of which 77% occurred
in men [18]. Reporting gonorrhoea to public health au-
thorities has been mandatory in Switzerland since 1988.
However, gonococcal susceptibility data in Switzerland
are sparse [19]. Due to the current N. gonorrhoeae resist-
ance problem, improving gonococcal antimicrobial re-
sistance surveillance is of utmost importance and high
on the agenda of the WHO’s “Global action plan to con-
trol the spread and impact of antimicrobial resistance in
Neisseria gonorrhoeae, 2012” [20]. Local antimicrobial sur-
veillance is essential for evidence-based treatment recom-
mendations. Given the lack of data, we investigated the
distribution of antibiotic susceptibility of N. gonorrhoeae
in specimens collected between 1990 and 2012.
Methods
All isolates were obtained in the northeastern part of
Switzerland and the region of Zurich between January
1990 and December 2012. Specimens were cultured
from symptomatic gonorrhoea patients with only one
isolate taken per patient in case they were infected at mul-
tiple sites. Species confirmation and susceptibility testing
was performed at the Institute of Medical Microbiology,
University of Zurich. Specimens were cultured on select-
ive media, i.e. until 2009 on Thayer Martin agar (Difco;
Becton, Dickinson and Company, Basel, Switzerland), sup-
plemented with IsoVitalex, and after 2009 on VCA3 agar
(BioMérieux, Marcy-l’Etoile, France). The commercial
biochemical gallery Api NH (BioMérieux) was used for
the identification.
Minimum inhibitory concentrations (MICs) for cefix-
ime, ceftriaxone, ciprofloxacin and penicillin were deter-
mined by the Etest method (BioMérieux, Marcy l’Etoile,
France) on Difco GC agar until 2004 (Becton Dickinson,
Cockeyswille, MD, USA) and after 2005 on chocolate
agar with PolyViteX (BioMérieux) or on MH-horse
blood agar (BioMérieux). In order to demonstrate the
comparability of the different methods, we tested 9 iso-
lates (1990–2004) and the reference ATCC strain 49226
with all three media for all four antibiotics (Additional
file 1: Table S1). Beta-lactamase test was performed with
nitrocefin (Becton Dickinson). The European Committee
on Antimicrobial Susceptibility Testing (EUCAST) break-
points were used [21]: Breakpoints for the definition ofdecreased cefixime and ceftriaxone susceptibility were
MICs >0.125 mg/L, and ciprofloxacin resistance was de-
fined by MICs >0.064 mg/L. Penicillin resistance was
defined by either MICs >1.0 mg/L or the presence of
penicillinase-producing strains.
The following data was available for all isolates col-
lected between 2005 and 2012: specimen source, date
specimen obtained, sex, age, and specimen site. For all
isolates collected before 2005 only date of specimen col-
lection was available. The study was approved by the
ethics committee of Zurich (ethics approval number:
KEK-ZH-Nr. 2012–0510).
Results
A total of 318 isolates from the region of Zurich and the
northeastern part of Switzerland were analysed, includ-
ing 42 samples from 1990, 66 from 2000 to 2004, and
210 samples from 2005 to 2012. The level of coverage
(number of isolates tested compared to the number of
reported cases in the region of Zurich) was 5%. Of the
samples collected between 2005 and 2012, 168 (79.3%)
were collected from men, 35 (16.5%) from women, and
in 9 (4.2%) samples data on sex and age was missing. Me-
dian age for males was 35 years (range 17 to 86 years) and
for females 31 years (range 16 to 66 years). The isolates
were obtained from the urethra (60%), cervix (13%), other
locations (4%), including anorectum, pharynx, joint and
eye, or from unknown sites (24%).
The results of antimicrobial susceptibilities are summa-
rized in Table 1. No decreased susceptibility to cefixime
was detected until 2006 in the tested strains, whereas
2007/2008 10.4%, 2009/2010 11.5%, and 2011/2012 11.4%
of isolates displayed in vitro resistance to cefixime. In
Figure 1 cefixime MIC distribution between 2005 and
2012 is illustrated. From 2005 onwards, isolates demon-
strate a clear shift towards higher MIC categories.
Ceftriaxone susceptibility was 100% until 2007. Be-
tween 2008 and 2010 four isolates exhibited decreased
susceptibility to ceftriaxone, with one isolate from
2008 showing a ceftriaxone MIC of 0.25 mg/L. In three
of these patients the site of infection was urethral and
in one patient anorectal. Most strains showed low
ceftriaxone MIC’s of ≤0.016 mg/L between 2005 and
2012. However, the proportion of isolates in higher
MIC categories has clearly increased in recent years
(Figure 2).
Fluoroquinolone-resistant N. gonorrhoeae emerged
in Switzerland during the 1990s, with a ciprofloxacin
resistance rate of 2.4% in 1990. In the early 2000s, a rapid
increase of ciprofloxacin resistance from 30.0% in 2001/
2002 to 72.7% in 2011/2012 was observed (Table 1).
Penicillin resistance rate was 22.7% in 2011/2012. How-
ever, only 18.2% of the strains were fully penicillin suscep-
tible according to EUCAST breakpoints (≤0.06 mg/L).
Table 1 N. gonorrhoeae with decreased susceptibility* to cefixime, ceftriaxone, and resistance to ciprofloxacin and
penicillin in Switzerland, 1990–2012
Cefixime Ceftriaxone Ciprofloxacin Penicillin
Year Tested, n# DS, n (%) (95% CI) Tested, n# DS, n (%) (95% CI) Tested, n# R, n (%) (95% CI) Tested, n# R, n (%) (95% CI)
1990 16 0 (0) (0–21) 16 0 (0) (0–21) 42 1 (2.4) (0–12) 42 9 (21.4) (10–37)
2000-2002 7 0 (0) (0–40) 7 0 (0) (0–40) 33 10 (30.3) (15–48) 33 4 (12.1) (3–28)
2003/2004 10 0 (0) (0–30) 10 0 (0) (0–30) 33 16 (48.5) (31–66) 33 13 (39.4) (23–58)
2005/2006 17 0 (0) (0–19) 32 0 (0) (0–11) 36 21 (58.3) (41–74) 31 7 (22.6) (10–41)
2007/2008 48 5 (10.4) (3.4-22) 85 2 (2.4) (0.3-8) 85 62 (72.9) (62–82) 84 25 (29.8) (20–41)
2009/2010 26 3 (11.5) (2.4-30) 43 2 (4.7) (0.5-16) 43 31 (72.1) (56–84) 43 7 (16.3) (7–30)
2011/2012 35 4 (11.4) (3.2-26) 46 0 (0) (0–8) 44 32 (72.7) (57–85) 44 10 (22.7) (11–38)
Total 159 239 317 311
Abbreviations: CI, confidence interval of the proportion; DS, decreased susceptibility; R, resistant.
*Decreased susceptibility to cefixime and ceftriaxone defined by minimal inhibitory concentration (MIC) >0.125 mg/L. Ciprofloxacin resistance defined by MIC >0.064 mg/L,
and penicillin resistance defined by MIC >1.0/L or penicillinase-producing strains, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
#The 42 isolates from 1990 and the 66 isolates from 2000–2004 were stored at −70°C and subcultured in 2005 for testing for penicillin and ciprofloxacin; and in
2011 for cefixime and ceftriaxone. The 36 strains from 2005/2006, the 85 strains from 2007/2008, the 43 strains from 2009/2010, and the 44 strains from 2011/2012 were
tested under routine conditions for penicillin, ciprofloxacin and ceftriaxone. In 2011 the viable strains were tested for cefixime. By the end of 2011, all strains were tested
routinely for penicillin, ciprofloxacin, ceftriaxone and cefepime. This explains why the number of strains tested in each period differs for each antibiotic.
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In Switzerland, N. gonorrhoeae strains with decreased
susceptibility to third-generation cephalosporins are
emerging. We observed increasing rates of cefixime re-
sistant strains, with a prevalence of 11% between 2007
and 2012. Moreover, ceftriaxone MICs are rising. The
proportion of isolates with elevated ceftriaxone MIC was
2.2% between 2007 and 2012.
Our findings are in line with the worldwide documented
decrease in cephalosporin susceptibility of N. gonorrhoeae.
In the European Gonococcal antimicrobial susceptibility
surveillance project (Euro-GASP), 9% of isolates displayed
decreased susceptibility to cefixime (MIC ≥0.25 mg/L) in
2010. Cefixime resistance rates were >5% in 11 of 21
European countries, and >15% in 5 countries, including
Austria, Denmark, Slovenia, Spain and Cyprus [22]. In the
United States the percentage of cefixime resistant isolates
(MIC ≥0.25 mg/L) increased from 0.1% in 2006 to 1.4% in
2011 [23]. The rise was most pronounced in the West0%
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Figure 1 Distribution of minimum inhibitory concentrations of Neisse
isolates. 2007/2008: 48 isolates. 2009/2010: 26 isolates. 2011/2012: 35 isolatewith resistance rates of 17% in Hawaii and 6.4% in San
Diego, California, in 2011 [17].
These are in vitro data and clinical cephalosporin resist-
ance has not yet been defined due to the fact that so far
there have been too few documented treatment failures in
order to establish a clear relationship between MIC and
clinical treatment failure. In a recently published Canadian
cohort study the rate of clinical treatment failure associ-
ated with isolates of N. gonorrhoeae with a cefixime MIC
of ≥0.12 mg/L was 25.0% compared to 1.9% of isolates
with a cefixime MIC of <0.12 mg/L [9].
In 2008, we isolated one strain with a MIC for ceftriaxone
of 0.25 mg/L. No decreased susceptibility to ceftriaxone
(MIC ≥0.25 mg/L) was detected from 2004 to 2010 among
Euro-GASP isolates. However, in correspondence to our
data, ceftriaxone MICs increased from 2009 onwards [22].
In the United States the percentage of isolates with elevated
ceftriaxone MICs (≥0.125 mg/L) rose slightly from 0% in
2006 to 0.4% in 2011 [17]. As displayed for cefixime, no.094 0.125 0.19 0.25 0.5
/L)
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ria gonorrhoea isolates for cefixime, 2005–2012. 2005/2006: 17
s. Abbreviation: MIC, minimum inhibitory concentration.
0%
10%
20%
30%
40%
50%
60%
70%
80%
0.016 0.023 0.032 0.047 0.064 0.094 0.125 0.19 0.25 0.5
Pe
rc
en
ta
ge
 o
f i
so
la
te
s
MIC (mg/L)
05/06
07/08
09/10
11/12
Figure 2 Distribution of minimum inhibitory concentrations of Neisseria gonorrhoea isolates for ceftriaxone, 2005–2012. 2005/2006: 29
isolates. 2007/2008: 85 isolates. 2009/2010: 43 isolates. 2011/2012: 46 isolates. Abbreviation: MIC, minimum inhibitory concentration.
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has been defined yet. Increasing MICs for cephalosporins,
however, may precede the emergence of resistance.
We found high ciprofloxacin resistance rates of N.
gonorrhoeae, with 72.7% in 2012. Our data demonstrates
that during the 1990s and early 2000s, when ciprofloxacin
was first choice for treatment, fluoroquinolone-resistant
isolates emerged, and rapidly increased after 2000, correlat-
ing with the observation in other countries around the
world [24-26]. By 2007, in the United States, and even earl-
ier in other regions, including Europe and Australia, fluoro-
quinolones were no longer recommended for the treatment
of gonococcal infections [27,28]. In Europe, ciprofloxacin
resistance was 53% (MIC ≥1 mg/L) in 2010 [22], and 13.3%
in the United States in 2011 (≥1 mg/L) [23].
The World Health Organization (WHO) recommends
discontinuation of empirical use of an antibiotic once 5%
of locally acquired gonococcal isolates are resistant [20].
The high rates of strains with decreased cefixime suscepti-
bility and first isolates with elevated MICs for ceftriaxone
shown by our data, support the recommendation of dual
therapy for gonococcal infections with ceftriaxone plus ei-
ther azithromycin or doxycycline. Combination regimens
have been adopted as strategies for the treatment of other
bacterial infections in the context of multidrug resistance
development. The oral cephalosporin, cefixime, should no
longer be used as first-line treatment.
In light of identified strains with decreased ceftriax-
one susceptibility, health-care providers need to be vigi-
lant for treatment failures, even in patients treated with
recommended antibiotic regimens. In persons treated
with alternative regimens, such as cefixime, test of cure
is recommended. Continued local surveillance of gono-
coccal antimicrobial susceptibility is important. Due to the
widespread use of nucleic acid amplification testing, cul-
ture for N. gonorrhoeae with antimicrobial susceptibility
testing is not routinely done in clinical practice.
To the best of our knowledge, this is the first report on
cephalosporin susceptibility testing of N. gonorrhoeae inSwitzerland. Longitudinal data on antimicrobial resistance
in gonococci over a period of more than two decades was
assessed. Nevertheless, the study has several limitations.
The level of coverage was relatively low, attributed in a
large part to the low number of gonococcal cultures taken
routinely in clinical practice. The samples were not system-
atically collected within a sentinella system, which may re-
sult in selection of specimens with a higher resistance rate.
Not all strains were tested for cephalosporins, which par-
ticularly concerns isolates obtained before 2006. However,
the subset of 20-30% of all isolates stored, none showed de-
creased susceptibility for cefixime and ceftriaxone. It is
therefore unlikely that we missed a relevant resistance sig-
nal. Finally, the isolates were not tested for azithromycin.
Conclusions
We found a high prevalence of N. gonorrhoeae with de-
creased susceptibility to cefixime, first strains with ele-
vated MICs for ceftriaxone, and high resistance rates to
ciprofloxacin. Treatment of gonorrhea with a combination
regimen with ceftriaxone plus azithromycin or doxycyc-
line is supported. Our data contributes to the global anti-
microbial resistance surveillance of N. gonorrhoeae, and
emphasizes the importance of further gonococcal anti-
microbial resistance testing.
Additional file
Additional file 1: Table S1. Minimal inhibitory concentrations for 9
Neisseria gonorrhoeae isolates (1990 – 2004) and for the reference ATCC
strain 49226 for penicillin, ceftriaxone, cefixime and ciprofloxacin on
chocolate agar with PolyViteX (BioMérieux), Difco GC agar (Becton
Dickinson, Cockeyswille, MD, USA), and on MH-horse blood agar
(BioMérieux) showing little variation.
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